Biomarkers Market Size to Record US$ 150.59 Bn through 2030


The global biomarkers market size is expected to be worth around US$ 150.59 billion by 2030, according to a new report by Vision Research Reports.

The global biomarkers market size was valued at US$ 53.18 billion in 2020 and is anticipated to grow at a CAGR of 16.2% during forecast period 2021 to 2030.

Get Sample Copy of This Report (Including TOC, List of Tables & Figures, and Chart)@

Biomarkers Market (By Type: Safety, Efficacy, Validation; By Application: Diagnostics, Drug Discovery & Development, Personalized Medicines, Others; By Disease: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

Report Coverage

Report Scope Details
Market Size USD 150.59 billion by 2030
Growth Rate CAGR of 16.2% From 2021 to 2030
Base Year 2021
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Type, Application, Disease
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Epigenetics AG; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Siemens Healthineers AG; Qiagen

Growth Factors

 The increasing prevalence of chronic diseases, advancements in the techniques used for the development of biomarker-based diagnostics, and the growing geriatric population are the key factors projected to boost the market growth over the forecast period. The rising number of COVID-19 cases across the globe and an increasing number of researches on the use of biomarkers for facilitating the detection & treatment of COVID-19 will also support market growth. by increasing collaborations & funds for R&D activities, rising consumer awareness, COVID-19 pandemic, and technological advancements in disease diagnosis. Research aids in the development of effective therapies for the treatment of various diseases, such as cancer, Cardiovascular Diseases (CVDs), immunological diseases, and neurological diseases.

Report Highlights

 The safety biomarkers segment held the largest market share of more than 40% in 2020, driven by the high awareness about routine health checkups, lowered drug attrition rate, and a rise in population that is at high risk of developing various diseases, such as cancer, cardiovascular conditions, and kidney disorders. The validation biomarkers segment is expected to exhibit the second-fastest growth over the forecast period owing to the use of these biomarkers in the pharmaceutical sector to predict the therapeutic failure of pharmaceutical molecules with low therapeutic profiles and distinct genetic profiles.

The drug discovery & development segment dominated the biomarkers market in 2020 with a revenue share of more than 33.5% owing to extensive R&D initiatives for the development of targeted therapeutics, the ability to predict drug efficacy more easily, and a fast-track approval process. One such instance is the launch of targeted therapy for EGFR mutation in Non-small Cell Lung Cancer (NSCLC) patients by Halozyme, Inc.

The diagnostics segment is estimated to register the fastest CAGR over the forecast period owing to advantages in early-stage detection of disease, this creates an opportunity for the diagnostic segment to propel early diagnosis and improve the rate of diagnosis.

The cancer segment held the largest market share of more than 37% in 2020, driven by a rise in demand for rapid and accurate diagnostic tools, an increase in global cancer burden, and an unmet need for more specific, personalized, therapeutic targets for cancer patients. Its use for early detection of cancer, estimate prognosis, and monitor response to the treatment is expected to drive the market.

North America accounted for the highest revenue share of more than 46% of the global market. The increasing disease burden, growing consumer awareness, proactive government actions, technological breakthroughs, and improvements in healthcare infrastructure can be attributed to this growth. For instance, in 2020, the Canadian Government-funded USD 79,000 research project for COVID-19 biomarkers.

Key Players

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Epigenetics AG
  • General Electric
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Qiagen

Market Segmentation

  • Type
    • Safety
    • Efficacy
    • Validation
  • Application
    • Diagnostics
    • Drug Discovery & Development
    • Personalized Medicines
    • Others
  • Disease
    • Cancer
      • Safety
      • Efficacy
      • Validation
    • Cardiovascular Diseases
      • Safety
      • Efficacy
      • Validation
    • Neurological Diseases
      • Safety
      • Efficacy
      • Validation
    • Immunological Diseases
      • Safety
      • Efficacy
      • Validation
    • Others
      • Safety
      • Efficacy
      • Validation
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Spain
      • France
      • Italy
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Australia
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Buy This Premium Research Report, click here@ or call: +1 9197 992 333


Daksh is an SEO Analyst having 3 years of experienced. we can quickly understand and support initiatives that will contribute to the goals and success of client campaigns. and also Perform keyword research in coordination with client business objectives to optimize existing content and uncover new opportunities.

View all posts by Daksh →

Leave a Reply

Your email address will not be published. Required fields are marked *